title: [A Patient with Recurrent Ulcerative Colitis-Associated Rectal Cancer Attaining a Complete Response with FOLFIRI plus Bevacizumab].
abstract: A 60-year-old man underwent laparoscopic total proctocolectomy with ileostomy for advanced ulcerative colitis-associated rectal cancer. The final diagnosis was advanced cancer pT3, pN2 and M0 (pStage Ⅲb). Adjuvant therapy with XELOX was performed. However, abdominal CT revealed a liver metastasis and lymph node metastases in the pelvis 6 months after surgery. The patient was treated with FOLFIRI plus bevacizumab. After 20 courses of chemotherapy, the patient was considered to have experienced a clinical CR, which has been maintained for 3 years 5 months.
authors.affiliation: Dept. of Surgical Oncology, Osaka City University Graduate School of Medicine.
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Iseki
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Maeda
authors.forename: Masatsune
authors.initials: M
authors.lastname: Shibutani
authors.forename: Hisashi
authors.initials: H
authors.lastname: Nagahara
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Ikeya
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Tamura
authors.forename: Go
authors.initials: G
authors.lastname: Ohira
authors.forename: Katsunobu
authors.initials: K
authors.lastname: Sakurai
authors.forename: Sadaaki
authors.initials: S
authors.lastname: Yamazoe
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Kimura
authors.forename: Takahiro
authors.initials: T
authors.lastname: Toyokawa
authors.forename: Naoshi
authors.initials: N
authors.lastname: Kubo
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Tanaka
authors.forename: Kazuya
authors.initials: K
authors.lastname: Muguruma
authors.forename: Kosei
authors.initials: K
authors.lastname: Hirakawa
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D003093:Colitis, Ulcerative / Q000150:complications*; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000601:surgery; D012008:Recurrence; D012074:Remission Induction
chemical_list: D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin